Chronic hepatitis C treatments, Sovalid and Harvoni passes the first door

Published: 2016-03-28 16:17:14

Updated: 2016-03-28 16:17:14

Chronic hepatitis C treatments, Sovaldi(sofosbuvir) and complex Harvoni(sofosbuvir, ledipasvir) have passed benefit adequacy evaluations.

This is a great news for the patient group damaged by the Dana Clinic crisis. The two drugs are applied by the benefit once the drug price negotiation is established in 60 days.

The Drug Benefit Deliberation Committee, Health Insurance Review & Assessment S...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.